Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2020.173548 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2020.173548 32926918!7486300!32926918     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32926918&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Pharmacol 2020 ; 886 (?): 173548 Nephropedia Template TP {{tp|p=32926918|t=2020. COVID-19 associated complications and potential therapeutic targets |pdf=|usr=}}{{32926918}} gab.com Text COVID-19 associated complications and potential therapeutic targets JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32926918 #FOAvip The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19. Twit Text FOAVip COVID-19 associated complications and potential therapeutic targets ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32926918 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32926918 #FOAvip English Wikipedia <ref>{{Cite pmid|32926918}}</ref> COVID-19 associated complications and potential therapeutic targets #MMPMID32926918 Monpara JD; Sodha SJ; Gupta PK Eur J Pharmacol 2020[Nov]; 886 (?): 173548 PMID32926918show ga The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19. |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*complications/*drug therapy[MESH] |Humans[MESH] |Molecular Targeted Therapy/*methods[MESH] |Pandemics[MESH]COVID-19 associated complications and potential therapeutic targets (epmc).pdf DeepDyve Pubget Overpricing